Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions

Palmerini, E., Maki, R. G., Staals, E. L., Alberghini, M., Antonescu, C. R., Ferrari, C., Ruggieri, P., Mavrogenis, A., Bertoni, F., Cesari, M., Paioli, A., Marchesi, E., Picci, P., Ferrari, S. (December 2014) Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions. Am J Clin Oncol, 37 (6). pp. 528-34. ISSN 1537-453X (Electronic)0277-3732 (Linking)

DOI: 10.1097/COC.0b013e31827defa1


BACKGROUND: Angiosarcoma of bone is a rare high-grade malignant vascular tumor. The literature regarding treatment and outcome of patients with this tumor is limited.We performed a 2 institutional retrospective study to analyze treatment and survival of patients with angiosarcoma of bone. PATIENTS AND METHODS: We reviewed patients with the histologic diagnosis of primary angiosarcoma of bone treated from 1980 to 2009. Demographic details, histology, treatment, and survival were reviewed. RESULTS: A total of 38 men and 22 women (median age, 54 y) were recruited. Most lesions occurred in the femur and the pelvis. Metastatic disease at presentation was diagnosed in 24 patients (40%). Forty-three patients underwent surgery, with 30 of them achieving surgical complete remission (SCR). Radiotherapy was applied to 17 patients, and chemotherapy to 13/35 and 15/22 patients with localized and metastatic disease, respectively.The 5-year overall survival (OS) was 20%: 33% for patients with localized disease and 0% for metastatic patients. Higher 5-year OS was reported for patients who achieved SCR (46%) than for those who did not (0%). In nonmetastatic patients, a trend toward improved survival was observed after SCR and adjuvant chemotherapy based on cisplatin, doxorubicin, and ifosfamide.Fifteen patients received chemotherapy for metastases. Two RECIST partial responses of 13 evaluable patients were documented (paclitaxel [n=1] and doxorubicin [n=1]). Stable disease was observed in 2 patients. CONCLUSIONS: Complete surgical resection is essential for outcome. Survival of patients with metastatic or unresectable disease is very poor. Activity of taxanes and anthracycline was observed in the metastatic setting and merits further evaluation.

Item Type: Paper
Uncontrolled Keywords: Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Bone Neoplasms/pathology/*therapy Child Cisplatin/administration & dosage Cohort Studies Disease-Free Survival Doxorubicin/administration & dosage Female Femoral Neoplasms/pathology/therapy Femur/pathology/surgery Hemangiosarcoma/pathology/*therapy Humans Humerus/pathology/surgery Ifosfamide/administration & dosage Male Methotrexate/administration & dosage Middle Aged Neoadjuvant Therapy Paclitaxel/administration & dosage Pelvic Bones/pathology/surgery Radiotherapy Radiotherapy, Adjuvant Radius/pathology/surgery Retrospective Studies Skull Neoplasms/pathology/surgery Spinal Neoplasms/pathology/surgery Treatment Outcome Ulna/pathology/surgery Young Adult
Subjects: diseases & disorders > cancer
diseases & disorders > cancer > cancer types > angiosarcoma
diseases & disorders > bone diseses
diseases & disorders > cancer > drugs and therapies
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: December 2014
Date Deposited: 20 Oct 2016 14:17
Last Modified: 20 Oct 2016 14:17
PMCID: PMC3681918
Related URLs:

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving